Navigation Links
Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007

Annual Revenues Increase 147% In First Full-Year Of Profitability

CARLSBAD, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory service provider, today reported revenues of $18.6 million for the fourth quarter ended December 31, 2007, an increase of 137% over revenues of $7.8 million for the comparable period in 2006. For the full year ended December 31, 2007, the Company reported revenues of $59.3 million, an increase of 147% over revenues of $24.0 million for the same period in 2006.

"We are proud of our accomplishments in 2007, moving first to profitability then to the public markets, all while growing our core business and building a solid infrastructure for continued expansion," said Tina Nova Bennett, Ph.D., President and CEO of Genoptix.

Fourth Quarter 2007

Gross profit for the fourth quarter of 2007 improved to $11.0 million, or 59% of revenues, from $4.0 million, or 51% of revenues, for the fourth quarter of 2006, a 175% improvement year-over-year resulting from an increase in sales and the leverage gained from additional case volumes.

Operating expenses for the fourth quarter of 2007 increased to $6.9 million from $4.3 million in the fourth quarter of 2006. These expenses were driven by investment in rapid organizational growth and ultimately contributed to operating income of $4.1 million in the fourth quarter of 2007, or 22% of revenues, as compared to a loss of $304 thousand during the same period in 2006.

GAAP net income for the fourth quarter of 2007 was $4.7 million, or diluted earnings per share (EPS) of $0.27, compared to a net loss of $358 thousand, or a net loss of $2.40 per diluted share, for the comparable period in 2006.

Full Year 2007

Gross profit for the full-year 2007 reached $35.2 million, pushing gross margins to 59%, up from $10.9 million, or 45% of revenues, for all of 2006. This improvement was primarily due to increases in case volume and service revenues resulting from an expanded sales effort and a net increase in Medicare reimbursement rates.

Operating expenses for 2007 increased to $22.2 million from $14.8 million for the full-year 2006, decreasing as a percentage of revenues to 37% for 2007, compared to 62% for all of 2006. Increased expenses were driven by the cost of additional personnel hired to support continued growth and infrastructure expansion. Operating income improved on a year-over-year basis, growing to just over $13 million at the end of 2007 from a loss of $3.9 million in 2006.

For the year, GAAP net income in 2007 increased to $13.4 million, $3.3 million of which is allocable to common shareholders, resulting in EPS of $0.78 on 4.2 million shares of weighted average common stock outstanding during the period. This compares to a net loss of $3.8 million, or a net loss of $33.74 per diluted share, for the full year 2006.

As of December 31, 2007, the Company's cash and cash equivalents and investment securities available-for-sale totaled $85.5 million compared to $3.9 million in the same period one year ago. Following completion of its IPO in November 2007, the Company received net proceeds of $72.5 million (after underwriting discounts, commissions and offering costs). For the full year ended December 31, 2007, cash generated from operations was $13.1 million, while purchases of capital equipment for the same period totaled $1.2 million.

"Once again, we improved our performance metrics over prior periods, ending the year with DSOs lowered to 52 days and further reducing bad debt expense to approximately 2% of our total revenues," said Sam Riccitelli, Genoptix EVP and COO. "Our solid operational execution and resulting cash flows support our reinvestment in future growth as we seek to enhance operational performance and provide added value to our core customers."

2008 Performance Outlook

For the full-year 2008, Genoptix expects revenues of approximately $90 million, resulting from expanded sales efforts and additional increases in case volumes.

The company also expects net income for 2008 of between $15 and $17 million (assuming an annual tax rate of 5% after utilizing our net operating loss carryforwards), which includes the impact of an estimated $6 million in non-cash stock-based compensation, an increase resulting primarily from expenses associated with the initiation of the Company's equity incentive programs. GAAP earnings per diluted share are expected to be in the range of $0.85 to $0.95 for the full year 2008.

Based on continued infrastructure expansion and implementation of its strategic plan, the Company is projecting capital expenditures of between $4 million and $6 million for the full-year 2008.

Conference Call Information

A conference call will take place on Tuesday, February 12, 2008, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time), hosted by President and CEO Tina Nova Bennett, Ph.D., and other members of senior management. To access the live conference call via phone, dial 888-713-4214 in the U.S. or Canada and 617-213-4866 for international callers. The participant code for the call is 56532675. A replay of the call will be available through Friday, February 22, 2008. Interested parties can access the rebroadcast by dialing 1-888-286-8010 or 1-617-801-6888 internationally and entering the reservation number 77232785.

The conference call will also be webcast live on the Internet and is accessible through the investor relations section of the Genoptix website at, or by accessing the external website, An online replay is planned to follow shortly after and will be available until Wednesday, March 12, 2008. To participate in the webcast, please connect to the Genoptix website several minutes prior to start time to register, download and install any necessary software that may be required.

About Genoptix, Inc.

Genoptix is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists. Genoptix is headquartered in Carlsbad, California.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release regarding the Company's business that are not historical facts may be considered "forward-looking statements," including statements regarding the value of the Company's services, the success of the Company's business model, the Company's ability to continue to expand its business and consistently provide specialized, personalized and comprehensive diagnostic services, the Company's growth prospects, DSOs, and the Company's financial guidance for 2008. Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause the Company's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from the results predicted include, without limitation, commercial and governmental reimbursement decisions, compliance and regulatory risks and the Company's ability to hire personnel and manage its growth and the competitive landscape within our industry. Certain other risks and uncertainties are detailed in the annual report on Form 10-K for the full-year period ended December 31, 2007 that was filed with the United States Securities and Exchange Commission on February 12, 2008. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Genoptix undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

[Financial tables follow]



(in thousands)

December 31,

2007 2006


Current assets:

Cash and cash equivalents $50,624 $3,865

Investment securities available-for-sale 34,836 -

Accounts receivable, net of allowance for

doubtful accounts 9,013 4,766

Other current assets 1,409 270

Total current assets 95,882 8,901

Property and equipment, net 1,950 1,287

Other long-term assets - 14

Total assets $97,832 $10,202

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable and accrued expenses $4,312 $1,987

Accrued compensation 2,496 1,058

Deferred revenue 95 39

Current portion of long-term debt - 1,524

Total current liabilities 6,903 4,608

Deferred rent 324 267

Long-term debt, net of current portion - 1,262

Commitments and contingencies

Stockholders' equity :

Preferred stock - 52

Common stock 16 -

Additional paid-in capital 132,532 59,362

Accumulated other comprehensive income 53 -

Accumulated deficit (41,996) (55,349)

Total stockholders' equity 90,605 4,065

Total liabilities and stockholders' equity $97,832 $10,202



(in thousands, except per share data)

Three Months Ended Years Ended

December 31, December 31,

2007 2006 2007 2006


Revenues $18,562 $7,828 $59,332 $24,018

Cost of revenues 7,563 3,823 24,106 13,131

Gross profit 10,999 4,005 35,226 10,887

Operating expenses:

Sales and marketing expenses 3,780 2,127 11,649 6,264

General and administrative expenses 2,979 1,962 9,976 6,930

Research and development expenses 96 220 559 1,080

Impairment and lease exit costs - - - 542

Total operating expenses 6,855 4,309 22,184 14,816

Income (loss) from operations 4,144 (304) 13,042 (3,929)

Interest income 817 53 1,062 246

Interest expense (122) (96) (353) (384)

Other income - (11) 41 308

Income (loss) before income taxes 4,839 (358) 13,792 (3,759)

Provision for income taxes (165) - (439) -

Net income (loss) $4,674 $(358) $13,353 $(3,759)

Net income (loss) per share(1)(2):

Basic $0.30 $(2.40) $1.20 $(33.74)

Diluted $0.27 $(2.40) $0.78 $(33.74)

Shares used to compute net income

(loss) per share:

Basic 10,367 149 2,756 111

Diluted 11,909 149 4,246 111

(1) As a result of the conversion of the Company's preferred stock into

11,032 shares of common stock upon completion of the Company's IPO in

November 2007, there is a lack of comparability in the basic and

diluted net income (loss) per share amounts for the periods presented

above. See Note 1 to the Notes to Consolidated Financial Statements in

the Annual Report on Form 10-K for the year ended December 31, 2007

for calculations of the pro forma net income (loss) per share for the

periods presented.

(2) For the three months ended December 31, 2007, $1,514 of the Company's

net income of $4,674 was allocated to preferred stockholders for

purposes of calculating net income per share pursuant to the terms of

the preferred stock, resulting in $3,160 of net income allocable to

common stockholders. For the year ended December 31, 2007, $10,036 of

the Company's net income of $13,353 was allocated to preferred

stockholders for purposes of calculating net income per share pursuant

to the terms of the preferred stock, resulting in $3,317 of net income

allocable to common stockholders. See Note 1 to the Notes to

Consolidated Financial Statements in the Annual Report on Form 10-K

for calculations of the pro forma net income (loss) per share for the

periods presented.

SOURCE Genoptix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Genoptix, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 12, 2008
2. Genoptix, Inc. Announces Pricing for Initial Public Offering
3. MIB Life Index Reports North American Life Insurance Activity Up 1.4% in December
4. NxStage Medical Reports Fourth Quarter and Full Year 2007 Results
5. Nutrition 21 Reports Fiscal Second Quarter 2008 Financial Results
6. Mesa Labs Reports Higher Quarterly Sales and Earnings
7. Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007
8. Palatin Technologies, Inc. Reports Fiscal Year 2008 Second Quarter Results; Teleconference and Webcast to be held on February 11, 2008
9. LCA-Vision Reports Fourth Quarter and Full-Year 2007 Financial Results
10. Neurobiological Technologies Reports Second Quarter Financial Results
11. Hawkins, Inc. Reports Third Quarter, Nine Months Fiscal 2008 Results
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... ... for mental health and wellness consultation, has collaborated with Women’s Web – ... their reader’s queries on topics on mental and emotional well-being relationship, life ...
(Date:11/25/2015)... ... November 25, 2015 , ... The holiday season is ... pleasing the palates of attendees is of the utmost importance. Whether you are ... get-together, give these recipes a try this holiday season. , Turkey Croquettes , ...
(Date:11/25/2015)... ... ... Dr. John Pierce, Medical Director at the Ageless Forever clinic in Las ... Pro laser therapy cap. FDA cleared for safety and efficacy, the Capillus272 offers men ... surgery, prescription pills, or topical foams. , “Capillus272™ Pro is a home-use device ...
(Date:11/25/2015)... ... November 25, 2015 , ... According to an article ... being more and more widely heralded as a breakthrough for performing hernia repairs. The ... over traditional laparoscopic surgery is that it can greatly reduce the pain that a ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... physicians and athletic programs, launches new Wimbledon Athletics Facebook page to ... young athletes for unsuspected cardiac abnormalities. About 2,000 people under the age of ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... PUNE, India , November 26, ... --> --> ... Research Report" and "Investigation Report on ... 2019 and 2021 forecasts data and ... library. . ...
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Cell Surface Marker Testing Market: Supplier ... to their offering.  --> ... of the  "2016 Future Horizons and ...
(Date:11/25/2015)... , Nov. 25, 2015  The American Academy ... Gynecologists (ACOG), and the March of Dimes cheered ... Protecting Our Infants Act of 2015 (S.799), ... of newborns born exposed to drugs, such as ... bill,s introduction, all three organizations have worked together ...
Breaking Medicine Technology: